Global Adult Vaccine Market Size study, by Type (Influenza, Pneumococcal, Hepatitis, Zoster, Meningococcal, HPV, DTP, Others), Application (Infectious Diseases, Travel Vaccines, Health Maintenance), and Regional Forecasts 2022-2032
The Global Adult Vaccine Market is valued approximately at USD 20.51 billion in 2023 and is anticipated to grow with a steady yet compelling growth rate of more than 6.13% over the forecast period 2024-2032. In an era driven by global public health priorities and increasing healthcare access, the adult vaccine market has emerged as a cornerstone of preventative medicine. As nations grapple with aging populations and the resurgence of vaccine-preventable diseases, the need to immunize beyond childhood has become imperative. This paradigm shift is reshaping immunization strategies and creating robust demand across a diverse range of vaccines—particularly those targeting influenza, shingles, hepatitis, and human papillomavirus (HPV). Adult vaccination, once an overlooked segment, now stands at the nexus of innovation, policy advocacy, and market expansion.
What elevates the trajectory of this market is its responsiveness to global disease burdens and governmental initiatives pushing adult immunization schedules. The mounting incidence of chronic conditions and weakened immunity with age are compelling healthcare providers and public health agencies to integrate adult vaccination into routine care models. Concurrently, travel and mobility trends have amplified the relevance of region-specific vaccinations, prompting demand for meningococcal, typhoid, and hepatitis vaccines. Additionally, the COVID-19 pandemic drastically heightened public awareness around the benefits of adult immunization, indirectly catalyzing broader vaccine uptake and solidifying trust in vaccination infrastructure.
The market is also benefitting from a wave of biotechnological innovations that are redefining vaccine production and delivery. Advances such as adjuvant systems, mRNA platforms, and needle-free delivery technologies are not only enhancing vaccine efficacy but also improving patient compliance and accessibility. Pharmaceutical giants are aggressively expanding their adult vaccine portfolios through strategic collaborations, accelerated regulatory pathways, and continuous investment in R&D. However, the high cost of certain vaccines, along with cold-chain logistics and disparities in coverage across low-income countries, remains a challenge to equitable distribution and sustained market penetration.
The evolving reimbursement landscape and inclusion of adult vaccines in national immunization programs are significantly improving affordability and accessibility across high-income regions. Meanwhile, targeted awareness campaigns and digital health tools are being deployed to address vaccine hesitancy and educate the population on the lifelong benefits of immunization. As a result, private and public partnerships are emerging as powerful engines to propel the market forward, especially in the realm of health maintenance and chronic disease prevention. Moreover, innovations in multi-dose packaging and temperature-stable formulations are enhancing distribution efficiencies, particularly in underserved regions.
Geographically, North America commands a leading position in the adult vaccine market, underpinned by robust healthcare infrastructure, advanced immunization schedules, and strong governmental backing. Europe follows closely, where regulatory harmonization and comprehensive health insurance policies bolster adult vaccine adoption. The Asia Pacific region is poised to be the fastest-growing market over the forecast period, driven by an increasing aging population, rising healthcare expenditure, and proactive public health strategies in countries like China, Japan, and India. Latin America and the Middle East & Africa are gradually unlocking potential through expanding healthcare networks and global immunization initiatives targeting adult populations.
Major market player included in this report are:
By Type
North America
What elevates the trajectory of this market is its responsiveness to global disease burdens and governmental initiatives pushing adult immunization schedules. The mounting incidence of chronic conditions and weakened immunity with age are compelling healthcare providers and public health agencies to integrate adult vaccination into routine care models. Concurrently, travel and mobility trends have amplified the relevance of region-specific vaccinations, prompting demand for meningococcal, typhoid, and hepatitis vaccines. Additionally, the COVID-19 pandemic drastically heightened public awareness around the benefits of adult immunization, indirectly catalyzing broader vaccine uptake and solidifying trust in vaccination infrastructure.
The market is also benefitting from a wave of biotechnological innovations that are redefining vaccine production and delivery. Advances such as adjuvant systems, mRNA platforms, and needle-free delivery technologies are not only enhancing vaccine efficacy but also improving patient compliance and accessibility. Pharmaceutical giants are aggressively expanding their adult vaccine portfolios through strategic collaborations, accelerated regulatory pathways, and continuous investment in R&D. However, the high cost of certain vaccines, along with cold-chain logistics and disparities in coverage across low-income countries, remains a challenge to equitable distribution and sustained market penetration.
The evolving reimbursement landscape and inclusion of adult vaccines in national immunization programs are significantly improving affordability and accessibility across high-income regions. Meanwhile, targeted awareness campaigns and digital health tools are being deployed to address vaccine hesitancy and educate the population on the lifelong benefits of immunization. As a result, private and public partnerships are emerging as powerful engines to propel the market forward, especially in the realm of health maintenance and chronic disease prevention. Moreover, innovations in multi-dose packaging and temperature-stable formulations are enhancing distribution efficiencies, particularly in underserved regions.
Geographically, North America commands a leading position in the adult vaccine market, underpinned by robust healthcare infrastructure, advanced immunization schedules, and strong governmental backing. Europe follows closely, where regulatory harmonization and comprehensive health insurance policies bolster adult vaccine adoption. The Asia Pacific region is poised to be the fastest-growing market over the forecast period, driven by an increasing aging population, rising healthcare expenditure, and proactive public health strategies in countries like China, Japan, and India. Latin America and the Middle East & Africa are gradually unlocking potential through expanding healthcare networks and global immunization initiatives targeting adult populations.
Major market player included in this report are:
- GlaxoSmithKline plc
- Pfizer Inc.
- Merck & Co., Inc.
- Sanofi
- Novavax, Inc.
- Johnson & Johnson
- Bavarian Nordic
- Serum Institute of India Pvt. Ltd.
- CSL Limited
- Emergent BioSolutions Inc.
- Astellas Pharma Inc.
- Takeda Pharmaceutical Company Limited
- Bharat Biotech
- Mitsubishi Tanabe Pharma Corporation
- Daiichi Sankyo Company, Limited
By Type
- Influenza Vaccines
- Pneumococcal Vaccines
- Hepatitis Vaccines
- Zoster Vaccines
- Meningococcal Vaccines
- HPV Vaccines
- DTP Vaccines
- Others
- Infectious Diseases
- Travel Vaccines
- Health Maintenance
North America
- U.S.
- Canada
- UK
- Germany
- France
- Spain
- Italy
- Rest of Europe
- China
- India
- Japan
- Australia
- South Korea
- Rest of Asia Pacific
- Brazil
- Mexico
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
- Historical year – 2022
- Base year – 2023
- Forecast period – 2024 to 2032
- Market Estimates & Forecast for 10 years from 2022 to 2032.
- Annualized revenues and regional level analysis for each market segment.
- Detailed analysis of geographical landscape with Country level analysis of major regions.
- Competitive landscape with information on major players in the market.
- Analysis of key business strategies and recommendations on future market approach.
- Analysis of competitive structure of the market.
- Demand side and supply side analysis of the market.
- GlaxoSmithKline plc
- Pfizer Inc.
- Merck & Co., Inc.
- Sanofi
- Novavax, Inc.
- Johnson & Johnson
- Bavarian Nordic
- Serum Institute of India Pvt. Ltd.
- CSL Limited
- Emergent BioSolutions Inc.
- Astellas Pharma Inc.
- Takeda Pharmaceutical Company Limited
- Bharat Biotech
- Mitsubishi Tanabe Pharma Corporation
- Daiichi Sankyo Company, Limited
CHAPTER 1. GLOBAL ADULT VACCINE MARKET EXECUTIVE SUMMARY
1.1. Global Adult Vaccine Market Size & Forecast (2022–2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Type
1.3.2. By Application
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
CHAPTER 2. GLOBAL ADULT VACCINE MARKET DEFINITION AND RESEARCH ASSUMPTIONS
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory Frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
CHAPTER 3. GLOBAL ADULT VACCINE MARKET DYNAMICS
3.1. Market Drivers
3.1.1. Aging populations and rising chronic disease burden
3.1.2. Pandemic-driven awareness and stronger immunization policies
3.1.3. Expanding international travel and region-specific vaccine demand
3.2. Market Challenges
3.2.1. High vaccine development and distribution costs
3.2.2. Cold-chain logistics and infrastructural gaps in low-income regions
3.2.3. Vaccine hesitancy and uneven coverage rates
3.3. Market Opportunities
3.3.1. Advances in novel platforms (mRNA, adjuvants, needle-free delivery)
3.3.2. Digital health tools and targeted awareness campaigns
3.3.3. Inclusion of adult vaccines in national immunization schedules
CHAPTER 4. GLOBAL ADULT VACCINE MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunity
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
CHAPTER 5. GLOBAL ADULT VACCINE MARKET SIZE & FORECASTS BY TYPE 2022–2032
5.1. Segment Dashboard
5.2. Global Adult Vaccine Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
5.2.1. Influenza Vaccines
5.2.2. Pneumococcal Vaccines
5.2.3. Hepatitis Vaccines
5.2.4. Zoster Vaccines
5.2.5. Meningococcal Vaccines
5.2.6. HPV Vaccines
5.2.7. DTP Vaccines
5.2.8. Others
CHAPTER 6. GLOBAL ADULT VACCINE MARKET SIZE & FORECASTS BY APPLICATION 2022–2032
6.1. Segment Dashboard
6.2. Global Adult Vaccine Market: Application Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
6.2.1. Infectious Diseases
6.2.2. Travel Vaccines
6.2.3. Health Maintenance
CHAPTER 7. GLOBAL ADULT VACCINE MARKET SIZE & FORECASTS BY REGION 2022–2032
7.1. North America Adult Vaccine Market
7.1.1. U.S. Adult Vaccine Market
7.1.1.1. Type breakdown size & forecasts, 2022–2032
7.1.1.2. Application breakdown size & forecasts, 2022–2032
7.1.2. Canada Adult Vaccine Market
7.2. Europe Adult Vaccine Market
7.2.1. UK Adult Vaccine Market
7.2.2. Germany Adult Vaccine Market
7.2.3. France Adult Vaccine Market
7.2.4. Spain Adult Vaccine Market
7.2.5. Italy Adult Vaccine Market
7.2.6. Rest of Europe Adult Vaccine Market
7.3. Asia Pacific Adult Vaccine Market
7.3.1. China Adult Vaccine Market
7.3.2. India Adult Vaccine Market
7.3.3. Japan Adult Vaccine Market
7.3.4. Australia Adult Vaccine Market
7.3.5. South Korea Adult Vaccine Market
7.3.6. Rest of Asia Pacific Adult Vaccine Market
7.4. Latin America Adult Vaccine Market
7.4.1. Brazil Adult Vaccine Market
7.4.2. Mexico Adult Vaccine Market
7.4.3. Rest of Latin America Adult Vaccine Market
7.5. Middle East & Africa Adult Vaccine Market
7.5.1. Saudi Arabia Adult Vaccine Market
7.5.2. South Africa Adult Vaccine Market
7.5.3. Rest of Middle East & Africa Adult Vaccine Market
CHAPTER 8. COMPETITIVE INTELLIGENCE
8.1. Key Company SWOT Analysis
8.1.1. GlaxoSmithKline plc
8.1.2. Pfizer Inc.
8.1.3. Merck & Co., Inc.
8.2. Top Market Strategies
8.3. Company Profiles
8.3.1. GlaxoSmithKline plc
8.3.1.1. Key Information
8.3.1.2. Overview
8.3.1.3. Financial (Subject to Data Availability)
8.3.1.4. Product Summary
8.3.1.5. Market Strategies
8.3.2. Pfizer Inc.
8.3.3. Merck & Co., Inc.
8.3.4. Sanofi
8.3.5. Novavax, Inc.
8.3.6. Johnson & Johnson
8.3.7. Bavarian Nordic
8.3.8. Serum Institute of India Pvt. Ltd.
8.3.9. CSL Limited
8.3.10. Emergent BioSolutions Inc.
8.3.11. Astellas Pharma Inc.
8.3.12. Takeda Pharmaceutical Company Limited
8.3.13. Bharat Biotech
8.3.14. Mitsubishi Tanabe Pharma Corporation
8.3.15. Daiichi Sankyo Company, Limited
CHAPTER 9. RESEARCH PROCESS
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes
1.1. Global Adult Vaccine Market Size & Forecast (2022–2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Type
1.3.2. By Application
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
CHAPTER 2. GLOBAL ADULT VACCINE MARKET DEFINITION AND RESEARCH ASSUMPTIONS
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory Frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
CHAPTER 3. GLOBAL ADULT VACCINE MARKET DYNAMICS
3.1. Market Drivers
3.1.1. Aging populations and rising chronic disease burden
3.1.2. Pandemic-driven awareness and stronger immunization policies
3.1.3. Expanding international travel and region-specific vaccine demand
3.2. Market Challenges
3.2.1. High vaccine development and distribution costs
3.2.2. Cold-chain logistics and infrastructural gaps in low-income regions
3.2.3. Vaccine hesitancy and uneven coverage rates
3.3. Market Opportunities
3.3.1. Advances in novel platforms (mRNA, adjuvants, needle-free delivery)
3.3.2. Digital health tools and targeted awareness campaigns
3.3.3. Inclusion of adult vaccines in national immunization schedules
CHAPTER 4. GLOBAL ADULT VACCINE MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunity
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
CHAPTER 5. GLOBAL ADULT VACCINE MARKET SIZE & FORECASTS BY TYPE 2022–2032
5.1. Segment Dashboard
5.2. Global Adult Vaccine Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
5.2.1. Influenza Vaccines
5.2.2. Pneumococcal Vaccines
5.2.3. Hepatitis Vaccines
5.2.4. Zoster Vaccines
5.2.5. Meningococcal Vaccines
5.2.6. HPV Vaccines
5.2.7. DTP Vaccines
5.2.8. Others
CHAPTER 6. GLOBAL ADULT VACCINE MARKET SIZE & FORECASTS BY APPLICATION 2022–2032
6.1. Segment Dashboard
6.2. Global Adult Vaccine Market: Application Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
6.2.1. Infectious Diseases
6.2.2. Travel Vaccines
6.2.3. Health Maintenance
CHAPTER 7. GLOBAL ADULT VACCINE MARKET SIZE & FORECASTS BY REGION 2022–2032
7.1. North America Adult Vaccine Market
7.1.1. U.S. Adult Vaccine Market
7.1.1.1. Type breakdown size & forecasts, 2022–2032
7.1.1.2. Application breakdown size & forecasts, 2022–2032
7.1.2. Canada Adult Vaccine Market
7.2. Europe Adult Vaccine Market
7.2.1. UK Adult Vaccine Market
7.2.2. Germany Adult Vaccine Market
7.2.3. France Adult Vaccine Market
7.2.4. Spain Adult Vaccine Market
7.2.5. Italy Adult Vaccine Market
7.2.6. Rest of Europe Adult Vaccine Market
7.3. Asia Pacific Adult Vaccine Market
7.3.1. China Adult Vaccine Market
7.3.2. India Adult Vaccine Market
7.3.3. Japan Adult Vaccine Market
7.3.4. Australia Adult Vaccine Market
7.3.5. South Korea Adult Vaccine Market
7.3.6. Rest of Asia Pacific Adult Vaccine Market
7.4. Latin America Adult Vaccine Market
7.4.1. Brazil Adult Vaccine Market
7.4.2. Mexico Adult Vaccine Market
7.4.3. Rest of Latin America Adult Vaccine Market
7.5. Middle East & Africa Adult Vaccine Market
7.5.1. Saudi Arabia Adult Vaccine Market
7.5.2. South Africa Adult Vaccine Market
7.5.3. Rest of Middle East & Africa Adult Vaccine Market
CHAPTER 8. COMPETITIVE INTELLIGENCE
8.1. Key Company SWOT Analysis
8.1.1. GlaxoSmithKline plc
8.1.2. Pfizer Inc.
8.1.3. Merck & Co., Inc.
8.2. Top Market Strategies
8.3. Company Profiles
8.3.1. GlaxoSmithKline plc
8.3.1.1. Key Information
8.3.1.2. Overview
8.3.1.3. Financial (Subject to Data Availability)
8.3.1.4. Product Summary
8.3.1.5. Market Strategies
8.3.2. Pfizer Inc.
8.3.3. Merck & Co., Inc.
8.3.4. Sanofi
8.3.5. Novavax, Inc.
8.3.6. Johnson & Johnson
8.3.7. Bavarian Nordic
8.3.8. Serum Institute of India Pvt. Ltd.
8.3.9. CSL Limited
8.3.10. Emergent BioSolutions Inc.
8.3.11. Astellas Pharma Inc.
8.3.12. Takeda Pharmaceutical Company Limited
8.3.13. Bharat Biotech
8.3.14. Mitsubishi Tanabe Pharma Corporation
8.3.15. Daiichi Sankyo Company, Limited
CHAPTER 9. RESEARCH PROCESS
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes
LIST OF TABLES
TABLE 1. Global Adult Vaccine market, report scope
TABLE 2. Global Adult Vaccine market estimates & forecasts by Region 2022–2032 (USD Million/Billion)
TABLE 3. Global Adult Vaccine market estimates & forecasts by Type 2022–2032 (USD Million/Billion)
TABLE 4. Global Adult Vaccine market estimates & forecasts by Application 2022–2032 (USD Million/Billion)
TABLE 5. Global Adult Vaccine market by segment, estimates & forecasts, 2022–2032 (USD Million/Billion)
TABLE 6. Global Adult Vaccine market by region, estimates & forecasts, 2022–2032 (USD Million/Billion)
TABLE 7. U.S. Adult Vaccine market estimates & forecasts, 2022–2032 (USD Million/Billion)
TABLE 8. U.S. Adult Vaccine market estimates & forecasts by segment, 2022–2032 (USD Million/Billion)
TABLE 9. Canada Adult Vaccine market estimates & forecasts, 2022–2032 (USD Million/Billion)
TABLE 10. Canada Adult Vaccine market estimates & forecasts by segment, 2022–2032 (USD Million/Billion)
TABLE 11. UK Adult Vaccine market estimates & forecasts, 2022–2032 (USD Million/Billion)
TABLE 12. Germany Adult Vaccine market estimates & forecasts, 2022–2032 (USD Million/Billion)
TABLE 13. France Adult Vaccine market estimates & forecasts, 2022–2032 (USD Million/Billion)
TABLE 14. Spain Adult Vaccine market estimates & forecasts, 2022–2032 (USD Million/Billion)
TABLE 15. Italy Adult Vaccine market estimates & forecasts, 2022–2032 (USD Million/Billion)
TABLE 16. Brazil Adult Vaccine market estimates & forecasts, 2022–2032 (USD Million/Billion)
TABLE 17. Mexico Adult Vaccine market estimates & forecasts, 2022–2032 (USD Million/Billion)
TABLE 18. China Adult Vaccine market estimates & forecasts, 2022–2032 (USD Million/Billion)
TABLE 19. India Adult Vaccine market estimates & forecasts, 2022–2032 (USD Million/Billion)
TABLE 20. Japan Adult Vaccine market estimates & forecasts, 2022–2032 (USD Million/Billion)
TABLE 1. Global Adult Vaccine market, report scope
TABLE 2. Global Adult Vaccine market estimates & forecasts by Region 2022–2032 (USD Million/Billion)
TABLE 3. Global Adult Vaccine market estimates & forecasts by Type 2022–2032 (USD Million/Billion)
TABLE 4. Global Adult Vaccine market estimates & forecasts by Application 2022–2032 (USD Million/Billion)
TABLE 5. Global Adult Vaccine market by segment, estimates & forecasts, 2022–2032 (USD Million/Billion)
TABLE 6. Global Adult Vaccine market by region, estimates & forecasts, 2022–2032 (USD Million/Billion)
TABLE 7. U.S. Adult Vaccine market estimates & forecasts, 2022–2032 (USD Million/Billion)
TABLE 8. U.S. Adult Vaccine market estimates & forecasts by segment, 2022–2032 (USD Million/Billion)
TABLE 9. Canada Adult Vaccine market estimates & forecasts, 2022–2032 (USD Million/Billion)
TABLE 10. Canada Adult Vaccine market estimates & forecasts by segment, 2022–2032 (USD Million/Billion)
TABLE 11. UK Adult Vaccine market estimates & forecasts, 2022–2032 (USD Million/Billion)
TABLE 12. Germany Adult Vaccine market estimates & forecasts, 2022–2032 (USD Million/Billion)
TABLE 13. France Adult Vaccine market estimates & forecasts, 2022–2032 (USD Million/Billion)
TABLE 14. Spain Adult Vaccine market estimates & forecasts, 2022–2032 (USD Million/Billion)
TABLE 15. Italy Adult Vaccine market estimates & forecasts, 2022–2032 (USD Million/Billion)
TABLE 16. Brazil Adult Vaccine market estimates & forecasts, 2022–2032 (USD Million/Billion)
TABLE 17. Mexico Adult Vaccine market estimates & forecasts, 2022–2032 (USD Million/Billion)
TABLE 18. China Adult Vaccine market estimates & forecasts, 2022–2032 (USD Million/Billion)
TABLE 19. India Adult Vaccine market estimates & forecasts, 2022–2032 (USD Million/Billion)
TABLE 20. Japan Adult Vaccine market estimates & forecasts, 2022–2032 (USD Million/Billion)
LIST OF FIGURES
FIG 1. Global Adult Vaccine market, research methodology
FIG 2. Global Adult Vaccine market, market estimation techniques
FIG 3. Global market size estimates & forecast methods
FIG 4. Global Adult Vaccine market, key trends 2023
FIG 5. Global Adult Vaccine market, growth prospects 2022–2032
FIG 6. Global Adult Vaccine market, Porter’s 5 force model
FIG 7. Global Adult Vaccine market, PESTEL analysis
FIG 8. Global Adult Vaccine market, value chain analysis
FIG 9. Global Adult Vaccine market by segment, 2022 & 2032 (USD Million/Billion)
FIG 10. Global Adult Vaccine market by segment, 2022 & 2032 (USD Million/Billion)
FIG 11. Global Adult Vaccine market by segment, 2022 & 2032 (USD Million/Billion)
FIG 12. Global Adult Vaccine market by segment, 2022 & 2032 (USD Million/Billion)
FIG 13. Global Adult Vaccine market by segment, 2022 & 2032 (USD Million/Billion)
FIG 14. Global Adult Vaccine market, regional snapshot 2022 & 2032
FIG 15. North America Adult Vaccine market 2022 & 2032 (USD Million/Billion)
FIG 16. Europe Adult Vaccine market 2022 & 2032 (USD Million/Billion)
FIG 17. Asia Pacific Adult Vaccine market 2022 & 2032 (USD Million/Billion)
FIG 18. Latin America Adult Vaccine market 2022 & 2032 (USD Million/Billion)
FIG 19. Middle East & Africa Adult Vaccine market 2022 & 2032 (USD Million/Billion)
FIG 20. Global Adult Vaccine market, company market share analysis (2023)
FIG 1. Global Adult Vaccine market, research methodology
FIG 2. Global Adult Vaccine market, market estimation techniques
FIG 3. Global market size estimates & forecast methods
FIG 4. Global Adult Vaccine market, key trends 2023
FIG 5. Global Adult Vaccine market, growth prospects 2022–2032
FIG 6. Global Adult Vaccine market, Porter’s 5 force model
FIG 7. Global Adult Vaccine market, PESTEL analysis
FIG 8. Global Adult Vaccine market, value chain analysis
FIG 9. Global Adult Vaccine market by segment, 2022 & 2032 (USD Million/Billion)
FIG 10. Global Adult Vaccine market by segment, 2022 & 2032 (USD Million/Billion)
FIG 11. Global Adult Vaccine market by segment, 2022 & 2032 (USD Million/Billion)
FIG 12. Global Adult Vaccine market by segment, 2022 & 2032 (USD Million/Billion)
FIG 13. Global Adult Vaccine market by segment, 2022 & 2032 (USD Million/Billion)
FIG 14. Global Adult Vaccine market, regional snapshot 2022 & 2032
FIG 15. North America Adult Vaccine market 2022 & 2032 (USD Million/Billion)
FIG 16. Europe Adult Vaccine market 2022 & 2032 (USD Million/Billion)
FIG 17. Asia Pacific Adult Vaccine market 2022 & 2032 (USD Million/Billion)
FIG 18. Latin America Adult Vaccine market 2022 & 2032 (USD Million/Billion)
FIG 19. Middle East & Africa Adult Vaccine market 2022 & 2032 (USD Million/Billion)
FIG 20. Global Adult Vaccine market, company market share analysis (2023)
